Obstetrics and Gynecology International
Volume 2015 (2015), Article ID 276095, 6 pages
http://dx.doi.org/10.1155/2015/276095

Research Article

Placental Oxidative Status throughout Normal Gestation in Women with Uncomplicated Pregnancies

Jayasri Basu, Bolek Bendek, Enyonam Agamasu, Carolyn M. Salafia, Aruna Mishra, Nerys Benfield, Ronak Patel, and Magdy Mikhail

Department of Obstetrics & Gynecology, Bronx Lebanon Hospital Center, 1650 Grand Concourse, Bronx, NY 10457, USA

Received 19 October 2014; Accepted 8 January 2015

Academic Editor: Gian Carlo Di Renzo

Copyright © 2015 Jayasri Basu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

The effects of gestational age on placental oxidative balance throughout gestation were investigated in women with uncomplicated pregnancies. Placental tissues were obtained from normal pregnant women who delivered at term or underwent elective pregnancy termination at 6 to 23 + 6 weeks of pregnancy. Placental tissues were analyzed for total antioxidant capacity (TAC) and lipid peroxide (malondialdehyde, MDA) levels using commercially available kits. Two hundred and one placental tissues were analyzed and the mean ± SD MDA (pmol/mg tissue) and TAC (µmol Trolox equivalent/mg tissue) levels for first, second, and third trimester groups were 277.01 ± 204.66, 202.66 ± 185.05, and 176.97 ± 141.61, P < 0.004 and 498.62 ± 400.74, 454.90 ± 374.44, and 912.19 ± 586.21, P < 0.0001 by ANOVA, respectively. Our data reflects an increased oxidative stress in the placenta in the early phase of normal pregnancy. As pregnancy progressed, placental antioxidant protective mechanisms increased and lipid peroxidation markers decreased resulting in diminution in oxidative stress. Our findings provide a biochemical support to the concept of a hypoxic environment in early pregnancy. A decrease in placental oxidative stress in the second and third trimesters appears to be a physiological phenomenon of normal pregnancy. Deviations from this physiological phenomenon may result in placental-mediated disorders.

1. Introduction

During the first trimester of pregnancy, the conceptus develops in a low oxygen environment that favors organogenesis in the embryo and angiogenesis in the placenta [1]. This low oxygen environment is created when maternal arterial blood is prevented from entering the intervillous space of the placenta by plugs of cytotrophoblast cells that invade the uterine spiral arteries. As pregnancy continues, higher concentrations of oxygen are required to support the rapid growth of the fetus and the placenta. At the end of first trimester, the maternal intraplacental circulation is fully established when cytotrophoblast cell plugs are dislodged, by an unknown mechanism and maternal blood flow to the intervillous space ensues. The normoxic environment thus created in the placenta is then maintained until term [1]. Perturbations in such an oxidative environment as pregnancy continues are suggested to play a role in the pathophysiology of pregnancy disorders such as preeclampsia, intrauterine growth restriction, and early pregnancy loss [1].

The altered hormonal status during pregnancy results in increased accumulation of maternal fat depots and hyperlipidemia [2]. Maternal plasma triglycerols and nonesterified fatty acids are reported to correlate with fetal lipid and fetal growth, suggesting that these molecules do traverse through the placenta [3]. The abundant presence of membrane phospholipids at sites where reactive oxygen species are formed makes them easily accessible endogenous targets for lipid peroxidation [4]. The free radical chemistry of lipid peroxidation is complex. Lipid peroxidation occurs as a chain reaction initiated by free radicals, which propagates itself and can result in the formation of many equivalents of lipid peroxides. MDA is one of the several low-molecular-weight end products formed from the decomposition of certain primary and secondary lipid peroxidation products. Nevertheless, MDA is not exclusively generated through lipid peroxidation. Oxidative modification of lipid can be induced in vitro or could occur in vivo during aging [5] and certain diseased conditions [6, 7]. The host of other lipid peroxidation products include: diene hydroperoxide, cyclic peroxides, bicyclic peroxides, or epoxy alcohol [7]. Of all these products of lipid peroxidation, MDA and 4-hydroxynonenal are naturally occurring biproducts. The determination of MDA is rather fairly simple and prompt. MDA readily participates with 2-thiobarbituric acid at a low pH and an elevated temperature. The reaction product is a 1 : 2 MDA-TBA adduct that is red in color, which can readily be determined colorimetrically. The ease of the assay has fostered MDA determination to be the most widely employed format for monitoring lipid peroxidation in a wide array of samples.

Efforts in understanding the increased oxidative stress during pathological states of pregnancy have been the focus of many studies in recent times. For this, investigators have measured lipid peroxides and antioxidant levels either in the blood or in the placenta of women, primarily with preeclampsia, and have compared the levels to that of normal women with uncomplicated pregnancies [8–12]. However, information regarding the change in placental oxidative stress throughout pregnancy is not well-studied. The objective of the present study was to investigate the effects of gestational age on the oxidative balance throughout gestation in women with uncomplicated pregnancies. In this study, the levels of placental malondialdehyde (MDA) were determined as a marker of lipid peroxidation and reactive oxygen species (ROS). Since a large number of antioxidants are present in our body in the form of several micro and macro molecules, as well as enzymes, and these molecules function synergistically in preventing oxidative stress, hence quantitative measurement of the total antioxidant capacity (TAC) of the placenta was simultaneously measured as a marker for antioxidant defenses.

2. Materials and Methods

The investigative protocol for this study was approved by the Institutional Review Board of the Bronx Lebanon Hospital Center. A total of 201 placental tissues were obtained from either normal pregnant women who delivered at term or from women who underwent elective pregnancy termination at 6 to 23 weeks and 6 days of pregnancy. Placental tissues from women with a history of hypertension or pregnancies that were complicated by diabetes, peripheral vascular disease, chronic renal disease, multifetal gestation, or major fetal anomalies were excluded from the study.

Placental samples were collected within 10 minutes of completion of the procedure. The locations of the placental tissues obtained following elective termination of pregnancies are unknown; however, placental tissues obtained in the third trimester were taken from one of the peripheral cotyledons. Each sample was washed thoroughly in saline to remove maternal blood and was then dissected in saline to identify chorionic villi without associated decidua. Villous samples were transported to the laboratory on ice and stored at −80°C until assay. The placental tissues were analyzed for TAC using TAC assay kit from Sigma Aldrich (St. Louis, MO, Catalog number CS0790). The principle of the assay is that, in the presence of hydrogen peroxide, metmyoglobin forms ferryl myoglobin radical which oxidizes ABTS (2,2′-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid)) to produce a radical cation ABTS·+. ABTS is colorless but when ABTS·+ is produced a soluble green colored chromogen is formed that can be determined spectrophotometrically at 750 nm. Antioxidants suppress the production of the radical cation in a concentration dependent manner and the color intensity decreases proportionately. Trolox, a water soluble vitamin E analog, is used in the assay to serve as a standard or control antioxidant. The lipid peroxidation (MDA) assay kit used for the study was obtained from Abcam (Cambridge, MA, Catalog # ab118970). The principle of the MDA assay is that MDA present in the sample is reacted with thiobarbituric acid (TBA) to generate MDA-TBA adduct. The MDA-TBA adduct is then quantified spectrophotometrically. For each assay, tissue homogenate was prepared using the buffer supplied with each kit and the assays were carried out as per the manufacturers’ instructions. A Tecan Infinite 200 Pro Microplate Reader was used for the assays. For MDA, the absorbance of the color was measured at 532 nm. MDA levels were expressed as pmol/mg tissue. For TAC, the absorbance was measured at 750 nm and the results were expressed as μmol Trolox equivalent/mg tissue. The intra-assay and interassay variations for both MDA and TAC were between 2–5% and 5–7%, respectively.

3. Statistical Analysis

Statistical evaluation of the data was carried out using statistical package version 22 [13]. Descriptive statistics was performed. Since the data was not normally distributed, Kruskal-Wallis test was performed to compare the differences among three trimester groups followed by Mann-Whitney test for intergroup comparisons. Spearman’s bivariate correlation was used to determine correlation between the MDA, TAC and gestational age in days and partial correlation was performed to determine the correlation between MDA and TAC after controlling for gestational age in days. A value of was considered statistically significant.

4. Results

In the study, a total of 201 placentas were evaluated for both MDA and TAC levels. Of these, 106 placental tissues were collected from women up to 13 weeks of gestation and were grouped as first trimester; 48 placental tissues were collected from women from 13⁺ to 23 weeks + 6 days of gestation and were grouped as second trimester; and 47 tissues were obtained from term normal placentas which were selected from deliveries of a newborn without maternal or fetal-neonatal pathologies and were grouped as third trimester.

Placental oxidative status throughout normal gestation is presented in Table 1. Placental MDA levels were the highest in the first trimester of normal pregnancy. In the second and third trimesters, placental MDA levels were progressively lower. Placental TAC levels on the other hand were found to be significantly higher in the third trimesters. A bar plot and depicting the effects of gestational age on placental MDA and TAC levels by trimester is presented in Figure 1. The mean maternal age between the trimester groups as shown in Table 1 was not significantly different. Kruskal-Wallis test (Table 2) revealed significant differences in both placental MDA and TAC levels (, , resp.), among the three trimester groups. Pairwise comparisons of MDA and TAC levels by trimester groups were performed using Mann-Whitney test and the results are presented in Tables 3 and 4, respectively. While the placental MDA levels were noted to decrease with an increase in gestational age, the TAC levels on the other hand showed an increase. Two scatter plots depicting the MDA and TAC levels with gestational age in days are presented in Figures 2 and 3. A downward trend in MDA and an upward trend in TAC levels can be seen as pregnancy progressed. Spearman’s bivariate correlation computed to determine the correlation between placental MDA and TAC levels with gestational age (GA, in days) showed a negative significant correlation between MDA and gestational age (, ). TAC and gestational age were positively correlated and the correlation was significant (, ). The correlation between MDA and TAC levels was negative (, 0.362) (Table 5). Partial correlation after controlling for gestational age between TAC and MDA was not significant (, ).

Table 1: Placental MDA and TAC levels throughout normal gestation.

Groups

MDA
TAC
Age

(pmol/mg tissue)
(μmol Trolox equivalent/mg tissue)
(yrs)

First trimester
106
277.01 ± 204.66
498.62 ± 400.74
26.77 ± 6.27

Second trimester
48
202.66 ± 185.05
454.90 ± 374.44
25.87 ± 6.50

Third trimester
47
176.97 ± 141.61
912.19 ± 586.21
26.83 ± 6.33

MDA: malondialdehyde; TAC: total antioxidant capacity. Data expressed as mean ± SD.

Placental MDA levels were highest in the first trimester and progressively declined thereafter, while TAC levels showed a significant increase beyond the second trimester of normal pregnancy.

Table 2: Comparison of placental MDA and TAC levels by trimester groups.

Groups

MDA
TAC

Mean rank
Mean rank

First trimester
106
114.39
91.44

Second trimester
48
86.81
85.52

Third trimester
47
85.30
138.37

MDA: malondialdehyde; TAC: total antioxidant capacity. Kruskal-Wallis test results.

The critical values for MDA and TAC levels were 11.895 ( < 0.003) and 25.665 ( < 0.0001), respectively.

Table 3: Pairwise comparison of placental MDA levels.

First trimester
Second trimester
Third trimester

Test Score, value
Test Score, value
Test score, value

First trimester
—
1885.0, 0.01
1731.0, 0.003

Second trimester

—
1106.0, 0.87

Third trimester

—

MDA: malondialdehyde; the nonparametric Mann-Whitney test was applied.

Significant differences were noted between first and second trimester ( < 0.01) and first and third trimester ( < 0.003) groups. The difference in MDA levels between second and third trimester groups was not significant.

Table 4: Pairwise comparison of placental TAC levels.

First trimester
Second trimester
Third trimester

Test score, value
Test score, value
Test score, value

First trimester
—
2394.0, 0.558
1327.5, 0.0001

Second trimester

—
535.0, 0.0001

Third trimester

—

TAC: total antioxidant capacity; the nonparametric Mann-Whitney test was applied.

Significant differences were noted between first and third trimester ( < 0.0001) and second and third trimester ( < 0.0001) groups. The difference in TAC levels between first and second trimester groups was not significant.

Table 5: Correlation between MDA, TAC, and gestational age.

MDA
TAC
GAD

Rho

Rho

Rho

MDA
1.000
—
−0.065
0.362
−0.191
0.007

TAC

1.000
—
0.262
0.0001

GAD

1.000
—

MDA: malondialdehyde; TAC: total antioxidant capacity; GAD: gestational age in days.

The nonparametric test Spearman’s correlation was applied. Results show significant negative correlations between MDA and GAD and significant positive correlation between TAC and GAD. MDA and TAC levels were negatively correlated, but the correlation was not statistically significant.

Figure 1: MDA: malondialdehyde; TAC: total antioxidant capacity. A box plot representating mean placental concentrations of TAC and MDA levels throughout gestation in normal pregnancy. The hatched bars represent mean placental TAC levels (μmol Trolox equivalent/mg tissue); the dotted bars represent mean placental MDA levels (pmol/mg tissue); and the error bars denote 95% CI.

Figure 2: MDA: malondialdehyde. The scatter plot showing a downward trend in placental MDA levels with an increase in gestational age in days.

Figure 3: TAC: total antioxidant capacity. The scatter plot showing an upward trend in placental TAC levels with an increase in gestational age in days.

5. Discussion

The results of the present study demonstrate that placental MDA levels were the highest in the first trimester of normal pregnancy. Thereafter, the levels showed a gradual decline as pregnancy continued and there was a negative correlation between placental MDA levels and gestational age (Table 5). On the other hand placental TAC levels were found to be the lowest in the first and second trimester but the levels steadily increased as pregnancy progressed (Table 1 and Figure 1). Our data are in agreement with an in vitro study which demonstrated that the production of lipid peroxide peaked in early placental samples but, by the end of pregnancy, there was minimal lipid peroxide produced [14]. In another previously reported study, the levels of conjugated diene, a breakdown product of lipid peroxidation, in the serum was found to rise more than 45% in the second trimester over the first trimester values but by the third trimester the levels declined [15].

Since lipid peroxide levels of the placenta in our study were the highest in the first trimester while the TAC levels were the lowest, the findings provide a biochemical support of the concept of the existence of physiologic hypoxia in the placenta during the first trimester. Our findings are in agreement with other nonbiochemical studies that also reported placental hypoxia in the first trimester [1, 16–18]. Morphological studies have shown that placental hypoxia occurs in the first trimester when extravillous trophoblast plugs block the maternal spiral arteries and prevent the maternal blood from entering the intervillous space [16]. In normal pregnancies, Doppler studies have confirmed the absence of blood flow into the intervillous space prior to 10 weeks of gestation [17]. Additionally, direct comparison of oxygen tension between the placenta and its adjacent endometrial tissue also revealed that the partial pressure of oxygen in the placenta was significantly lower compared to that of the endometrium [18]. Investigators believe that such a hypoxic environment in the first trimester is essential for the regulation of trophoblast differentiation, embryogenesis, and/or placental development for a normal pregnancy outcome. The oxidative status of the placenta is not geographically homogenous. At high altitude, where the partial pressure of oxygen is low, placental hypoxic stress is induced that thwarts the high-altitude pregnancies more toward a preeclamptic phenotype [19].

For normal pregnancy to progress efficiently, the transition from a hypoxic to a normoxic environment is vitally important. During first trimester, antioxidant mechanisms are induced in the placenta to neutralize the excess accumulation of ROS and to trigger mechanisms that can remove or repair any damaged cells [20]. Our study shows that placental oxidative stress wanes off as normal pregnancy continues. By third trimester, a progressive increase in TAC levels was noted with a simultaneous decrease in MDA levels compared to the first trimester values (Tables 1, 3, and 4). Similar results of higher serum TAC levels in the third trimester of normal pregnancy over the first trimester values have also been previously reported [21]. Our results indicate that by the third trimester placental antioxidant protection mechanisms become efficient enough to counteract the oxidative challenge. Failure to establish such efficient antioxidant protection may contribute to the development of preeclampsia.

Low oxygen environment favors the generation of ROS which are characterized as molecules having one or more unpaired electrons [22]. The unpaired electron gives considerable reactivity to the free radicals and their nonradical intermediates. Recent in vitro, cell culture, and animal model studies have confirmed that ROS can activate a variety of transcription factors and protein kinases, influence the expression of a number of genes, are involved in signal transduction pathways, and can act as subcellular messengers for certain growth factors [22–26]. Placental adaptation in response to low oxygen tension occurs early in the pregnancy and during the process ROS act as key cell signaling molecules [24–26]. The increased levels of lipid peroxide in the first trimester of pregnancy in our study could reflect a period when excessive production of ROS might have taken place (Table 1). The physiological role of ROS during early pregnancy is suggested to influence a number of functions including remodeling of the spiral arteries, angiogenesis, and proliferation of the cytotrophoblast cells. Additionally, increased ROS in the placenta in the early phase of normal pregnancy has been shown to alter cell permeability and vascular biology, stimulate cellular and matrix remodeling, and protect the fetus from intrauterine infection [24–27]. The increased production of ROS in the first trimester of normal pregnancy could induce cytotrophoblast proliferation and the expression of key developmental genes involved in embryogenesis and placental development. This increase in cytotrophoblast proliferation in the first trimester is suggested by Douglas and Haddad [28] to be a natural protective mechanism to establish a mature placenta in advance of the period of rapid fetal growth.

Our study has limitations. The short questionnaire that was approved by our Institutional Review Board for the study included collecting information on maternal age, parity, gestational age as confirmed by ultrasound, and infection status. Smoking status of the patients, though was included in the questionnaire, was, however, not strictly monitored. Moreover, information on dietary and/or vitamin intake throughout the gestational period was not included. It is noteworthy, however, that the catchment area of the Bronx from where the pregnant women came from comprised primarily of African American (38%) and Hispanic (52%) descent. A previous study carried out on women from the same catchment area of the Bronx revealed that dietary and vitamin intakes were comparable between the pregnant and the nonpregnant groups (unpublished data).

Oxidative stress status in human placentas throughout normal pregnancy has not been well studied previously. Correlating the fetal blood oxidative status to the placenta and the placenta to the maternal systemic blood could ideally reflect the placental oxidative status and perhaps would be highly desirable. The focus of this study was in understanding the placental oxidative status throughout normal gestation. Comparative investigation of cord blood and maternal blood samples to identify any association can only be carried out in late stage of pregnancy and needs to be addressed in future studies. Our findings demonstrate that a decrease in oxidative stress with increase in gestational age may be a normal physiological phenomenon of normal pregnancy. Our data demonstrate the presence of a placental oxidative stress in the first trimester when the placental MDA levels are significantly high, with minimum protection offered by placental antioxidant system. As pregnancy progresses, the placental environment switches to a normoxic state as reflected by a gradual increase in the total antioxidant capacity of the placenta and a decrease in lipid peroxidation markers. By the third trimester, our results show that placental antioxidant mechanisms become more efficient to counteract the oxidative challenge. Deviation from this physiological balance whether caused by increased generation of ROS or decreased neutralization by antioxidants can cause placental damage and may contribute to abnormal pregnancy outcome.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

The authors would like to thank the staff nurses in the Department of OB/GYN, Bronx Lebanon Hospital Center, for their support and Elaine Marchi of the Basic Research Institute, Staten Island, NY, for her contribution in the initial set up of the study.

References

G. J. Burton and E. Jauniaux, “Oxidative stress,” Best Practice and Research: Clinical Obstetrics and Gynaecology, vol. 25, no. 3, pp. 287–299, 2011.

D. Mankuta, M. Elami-Suzin, A. Elhayani, and S. Vinker, “Lipid profile in consecutive pregnancies,” Lipids in Health and Disease, vol. 9, article 58, 2010.

E. Harrera and H. Ortega-Senovilla, “Lipid metabolism during pregnancy and its implications for fetal growth,” Current Pharmaceutical Biotechnology, vol. 15, no. 1, pp. 24–31, 2014.

L. L. de Zwart, J. H. N. Meerman, J. N. M. Commandeur, and N. P. E. Vermeulen, “Biomarkers of free radical damage applications in experimental animals and in humans,” Free Radical Biology and Medicine, vol. 26, no. 1-2, pp. 202–226, 1999.

D. Harman, “Free radical theory of aging: an update—increasing the functional life span,” Annals of the New York Academy of Sciences, vol. 1067, no. 1, pp. 10–21, 2006.

D. A. Slatter, C. H. Bolton, and A. J. Bailey, “The importance of lipid-derived malondialdehyde in diabetes mellitus,” Diabetologia, vol. 43, no. 5, pp. 550–557, 2000.

A. Ayala, M. F. Muñoz, and S. Argüelles, “Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal,” Oxidative Medicine and Cellular Longevity, vol. 2014, Article ID 360438, 31 pages, 2014.

R. E. Little and B. C. Gladen, “Levels of lipid peroxides in uncomplicated pregnancy: a review of the literature,” Reproductive Toxicology, vol. 13, no. 5, pp. 347–352, 1999.

M. S. Mikhail, A. Anyaegbunam, D. Garfinkel, P. R. Palan, J. Basu, and S. L. Romney, “Preeclampsia and antioxidant nutrients: decreased plasma levels of reduced ascorbic acid, α-tocopherol, and beta-carotene in women with preeclampsia,” The American Journal of Obstetrics and Gynecology, vol. 171, no. 1, pp. 150–157, 1994.

P. R. Palan, M. S. Mikhail, and S. L. Romney, “Placental and serum levels of carotenoids in preeclampsia,” Obstetrics and Gynecology, vol. 98, no. 3, pp. 459–462, 2001.

Y. Takehara, T. Yoshioka, and J. Sasaki, “Changes in the levels of lipoperoxide and antioxidant factors in human placenta during gestation,” Acta Medica Okayama, vol. 44, no. 2, pp. 103–111, 1990.

A. Agarwal, A. Aponte-Mellado, B. J. Premkumar, A. Shaman, and S. Gupta, “The effects of oxidative stress on female reproduction: a review,” Reproductive Biology and Endocrinology, vol. 10, article 49, 2012.

IBM SPSS Statistics for Windows, version 22, IBM Corporation, Armonk, NY, USA

K. Sekiba and T. Yoshioka, “Changes of lipid peroxidation and superoxide dismutase activity in the human placenta,” The American Journal of Obstetrics and Gynecology, vol. 135, no. 3, pp. 368–371, 1979.

J. Uotila, R. Tuimala, T. Aarnio, K. Pyykko, and M. Ahotupa, “Lipid peroxidation products, selenium-dependent glutathione peroxidase and vitamin E in normal pregnancy,” European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 42, no. 2, pp. 95–100, 1991.

G. J. Burton, E. Jauniaux, and A. L. Watson, “Maternal arterial connections to the placental intervillous space during the first trimester of human pregnancy: the Boyd Collection revisited,” The American Journal of Obstetrics and Gynecology, vol. 181, no. 3, pp. 718–724, 1999.

L. Valentin, P. Sladkevicius, R. Laurini, H. Söderberg, and K. Marsal, “Uteroplacental and luteal circulation in normal first-trimester pregnancies: Doppler ultrasonographic and morphologic study,” The American Journal of Obstetrics and Gynecology, vol. 174, no. 2, pp. 768–775, 1996.

E. Jauniaux, A. Watson, O. Ozturk, D. Quick, and G. Burton, “In-vivo measurement of intrauterine gases and acid-base values early in human pregnancy,” Human Reproduction, vol. 14, no. 11, pp. 2901–2904, 1999.

S. K. Palmer, L. G. Moore, D. A. Young, B. Cregger, J. C. Berman, and S. Zamudio, “Altered blood pressure course during normal pregnancy and increased preeclampsia at high altitude (3100 meters) in Colorado,” The American Journal of Obstetrics and Gynecology, vol. 180, no. 5, pp. 1161–1168, 1999.

A. Mueller, C. Koebnick, H. Binder et al., “Placental defence is considered sufficient to control lipid peroxidation in pregnancy,” Medical Hypotheses, vol. 64, no. 3, pp. 553–557, 2005.

V. Toescu, S. L. Nuttall, U. Martin, M. J. Kendall, and F. Dunne, “Oxidative stress and normal pregnancy,” Clinical Endocrinology, vol. 57, no. 5, pp. 609–613, 2002.

T. Finkel, “Oxygen radicals and signaling,” Current Opinion in Cell Biology, vol. 10, no. 2, pp. 248–253, 1998.

R. G. Allen and M. Tresini, “Oxidative stress and gene regulation,” Free Radical Biology and Medicine, vol. 28, no. 3, pp. 463–499, 2000.

P. A. Dennery, “Effects of oxidative stress on embryonic development,” Birth Defects Research Part C—Embryo Today, vol. 81, no. 3, pp. 155–162, 2007.

L. Myatt, “Review: reactive oxygen and nitrogen species and functional adaptation of the placenta,” Placenta, vol. 31, supplement A, pp. S66–S69, 2010.

D. S. Charnock-Jones, P. Kaufmann, and T. M. Mayhew, “Aspects of human fetoplacental vasculogenesis and angiogenesis. I. Molecular regulation,” Placenta, vol. 25, no. 2-3, pp. 103–113, 2004.

S.-Y. Oh, T. Chu, and Y. Sadovsky, “The timing and duration of hypoxia determine gene expression patterns in cultured human trophoblasts,” Placenta, vol. 32, no. 12, pp. 1004–1009, 2011.

R. M. Douglas and G. G. Haddad, “Genetic models in applied physiology: invited review: effect of oxygen deprivation on cell cycle activity: a profile of delay and arrest,” Journal of Applied Physiology, vol. 94, no. 5, pp. 2068–2083, 2003.